Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 14/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3269563 | 0.71 | NOTUM (0.53) | NOTUMCYP11B2CYP11B1 | |
| SCHEMBL3265855 | 0.68 | SOAT1 (0.61) | NOTUM | |
| SCHEMBL6322481 | 0.66 | NOTUM (0.46) | NOTUMCYP11B2 | |
| SCHEMBL20939323 | 0.66 | NOTUM (0.56) | NOTUMCYP11B2 | |
| SCHEMBL20939587 | 0.66 | NOTUM (0.46) | NOTUMCYP11B2 | |
| SCHEMBL1761149 | 0.65 | NOTUM (0.61) | NOTUMCYP11B2MEN1KMT2ACYP11B1 | |
| SCHEMBL20939398 | 0.65 | CYP11B2 (0.48) | NOTUMCYP11B2 | |
| SCHEMBL8824021 | 0.65 | NOTUM (0.49) | NOTUMMEN1KMT2A | |
| SCHEMBL6685699 | 0.64 | NOTUM (0.64) | NOTUMCYP11B2PKMCYP11B1 | |
| SCHEMBL18369759 | 0.63 | ALDH1A1 (0.51) | NOTUMCYP11B2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1541553-B1 | INDOLINE COMPOUND AND MEDICINAL USE THEREOF | KYOTO PHARMA IND (JP) | 2010-06-02 | — | — | EP | disclosed |
| US-7429612-B2 | Indoline compound and medicinal use thereof | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2008-09-30 | — | — | US | disclosed |
| US-20060128787-A1 | Novel indoline compound and medicinal use thereof | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2006-06-15 | — | — | US | disclosed |
| CN-1681781-A | Novel indoline compound and medicinal use thereof | KYOTO PHARMA IND (JP) | 2005-10-12 | — | — | CN | disclosed |
| EP-1541553-A1 | NOVEL INDOLINE COMPOUND AND MEDICINAL USE THEREOF | Kyoto Pharmaceutical Industries, Ltd. (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128787-A1 | Novel indoline compound and medicinal use thereof | ACAT2, ACAT1, ACOX1 | NOTUM 219/4885CYP11B2 79/4885PKM 2109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.